Key Takeaways
- Margin story intact, top line soft: EBITDA margin improved to 21.1% in H1 (up from 17.7% YoY) driven by mix and cost control, even as overall revenue growth stayed at mid-single digits.
- U.S. reset is deliberate and painful: U.S. revenue fell 15% in H1 as management exited unviable products and absorbed supply-chain penalties; profitability improved, and the business is now restocked to win back lost customers from Q4 onward.
- Domestic growth trails the market by design: India grew ~1% below the market because the company walked away from low-margin injectable anti-infectives and carries a heavier acute mix in a slow acute market; chronic is growing much faster and will keep pulling the mix upward.
- FY25 guidance held, H2-weighted: Management reaffirmed 8–9% domestic growth, mid-single-digit overall top line growth, and 18.5–19% EBITDA margin, with Q4 expected to be the strongest quarter on a favorable base and demand-side work.
- What to watch next quarter: Whether the U.S. inventory rebuild actually converts to revenue and customer wins in Q4, the pace of anti-infectives recovery domestically, and any update on the sacubitril-valsartan litigation that could unlock a U.S. launch.
U.S. Business: Profitability Over Top Line
- H1 degrowth unpacked: The 15% decline came from three forces: ~6% price erosion in vanilla generics, supply-chain failures that lost contracts, and a deliberate strategy to exit unviable products rather than chase revenue. Last year’s failure-to-supply penalties alone were ₹140 crores.
- Profitability improved despite the top-line hit: Efficiency measures, exiting low-margin products, and a better product mix lifted U.S. profitability in H1 versus H1 last year. Management’s stated intent is to get U.S. EBITDA closer to the company’s overall margin over time so it stops being dilutive.
- Inventory rebuilt to fix the supply problem: Inventory was purposely increased because FY24 levels had fallen so low they triggered the penalties and customer losses. Back orders have already dropped from 38% to 2%, and management expects the rebuilt inventory to produce positive results from Q4 onward by ensuring supplies and winning back lost customers.
- FY25 outlook: Flattish to mid-single-digit erosion on the top line for the full year, with H2 better than H1. Profitability is expected to keep improving through H2.
- Pipeline watchpoints: One small differentiated product launched in Q2. Sacubitril-valsartan approval is in hand but tied up in litigation with Novartis; launch timing depends on how that proceeds. Mirabegron is bound by an innovator settlement and will launch only post-FY26. A cGMP approval with 180-day exclusivity is expected to launch in Q3.
Vikas Gupta: "Rather than just chasing our top line, I think our focus largely on U.S. business has been on improving the profitability."
Domestic Formulation: Acute Drag, Chronic Pull
- Growth gap explained: The domestic business grew ~1% below the overall market. The company carries a higher weight of acute products in a market where acute growth has been slow, and it deliberately sacrificed volume in low-margin injectable anti-infectives to protect profitability. Internal efficiency measures also created some friction.
- Anti-infectives lost share, corrective action underway: Brands like Clavam, Xone, and Taxim gave up market share as smaller players returned post-COVID and Eastern India, a key geography, slowed. Management views this as a short-term fluctuation and says corrective measures have been taken; coming quarters should show better performance.
- Chronic is the offset and the future: Chronic therapies are growing much faster than acute, both because the chronic market itself is growing faster and because Alkem’s chronic base is smaller. Management expects chronic growth to be “much, much higher” than market growth over the next three years, which will steadily improve the chronic share of the portfolio.
- Brand-level bright spots: Pan, Pan D, Pipzo, A To Z, and Uprise-D3 are all delivering significant growth, some at their highest rates in recent memory. Management sees more positives than concerns in the domestic business.
- Full-year confidence held at 8–9%: H2 is expected to be better than H1, with Q4 particularly strong, partly on a favorable base (Q4 last year saw 2% degrowth) and partly on demand-side work and chronic momentum.
Vikas Gupta: "I guess there are more positives than concerns in our domestic business that we have. And that's why we are very bullish of our overall growth of 8% to 8.5% as far as the overall year is concerned."
Margin Walk & Levers
- H1 margin jump: EBITDA margin improved to 21.1% in H1 FY25 from 17.7% in H1 FY24, a gain of ~340 bps. The drivers were strategic: prioritizing a high-margin product mix, implementing cost controls, and benefiting from lower API prices.
- Gross margin got a three-way lift: Lower API costs, a reduced share of lower-margin U.S. sales, and an improved product mix within both international (higher ROW contribution) and domestic business all pushed gross margins higher.
- Full-year margin guidance: 18.5% to 19% EBITDA margin for FY25, an improvement of ~100 bps over the prior year. Management’s medium-term ambition is to improve EBITDA by at least 100 bps every year, with 25% as a destination reached over a period of time.
- Pre-operating cost headwind ahead: MedTech and the Enzene biosimilars plant will together add at most ₹60–70 crores in pre-operative expenses, flowing through Q3 and Q4. The Enzene plant is expected to begin production in Q4 FY25 or Q1 FY26 and to break even in its first year, with an order book already started.
- Trade generics improving: The trade generic business is seeing good margin improvement from a better mix and better pricing.
International & Emerging Bets
- ROW growth running at 30%: Management expects this pace to continue, supported by more filings, strategic partnerships, and out-licensing partners. Results from new dossiers will begin to show two years from now.
- Enzene biosimilars plant nearing readiness: Production start is targeted for Q4 FY25 to Q1 FY26. The plant already has an order book and is expected to break even in year one. At least two to three biosimilar products will be clearly defined for the five-year plan.
- MedTech entry via Exactech: A licensing and technical know-how transfer agreement was signed with Exactech, a U.S. hip and knee replacement company, for the MedTech business. Exactech is currently in bankruptcy proceedings, but management confirmed the technical transfer is ongoing and banks have already assigned the agreement to Alkem; operationally, they see no challenge. Product launch is planned for Q1 or Q2 of next financial year.
Capital Allocation & M&A
- Noncurrent investments repositioned: Money previously parked in fixed deposits is now being placed in NCDs and AAA+ mutual funds. The shift makes the investments marketable and tradable so they can be deployed quickly for M&A without penalties.
- M&A filter is explicit: Management is looking for strategic opportunities where Alkem can add value and create synergy. The minimum IRR threshold is 14–15%, set against a cost of capital of ~12%.
Nitin Agarwal: "Our cost of capital is around 12%, so -- and so definitely, we'll not go anything which is lower than the 14% to 15% of IRR."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Domestic formulation growth | 8% to 9% for FY25; H2 better than H1, Q4 particularly strong | FY25 |
| Overall top line growth | Mid-single-digit for FY25 | FY25 |
| EBITDA margin | 18.5% to 19% for FY25; improve by at least 100 bps annually thereafter | FY25 and beyond |
| U.S. top line | Flattish to mid-single-digit erosion for FY25; H2 better than H1 | FY25 |
| U.S. profitability | Continue improving in H2; eventually converge toward overall company EBITDA margin | H2 FY25 and over time |
| Enzene plant production start | Q4 FY25 to Q1 FY26; break even in first year | Q4 FY25–Q1 FY26 |
| MedTech product launch | Q1 or Q2 of next financial year | Q1–Q2 FY26 |
| Mirabegron U.S. launch | Bound by innovator settlement; launch only post-FY26 | Post-FY26 |
| cGMP product with 180-day exclusivity | Launch expected in Q3 | Q3 FY25 |
| Pre-operative expenses (MedTech + Enzene) | At most ₹60–70 crores, flowing in Q3 and Q4 | Q3–Q4 FY25 |
| Chronic business growth | Much higher than market growth, improving chronic share of portfolio | Next 3 years |
| M&A IRR threshold | Minimum 14% to 15% | Ongoing |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Net profit | ₹688.6 cr, +11% YoY |
| EBITDA (H1 FY25) | ₹1,361.5 cr, margin of 21.1% vs 17.7% in H1 FY24 |
| Revenue from operations (H1 FY25) | +0.6% YoY growth |
| Full-year EBITDA margin guidance | 18.5% to 19%, improvement of ~100 bps YoY |
| Full-year revenue growth guidance | Mid-single-digit growth |
| India business growth guidance | 8% to 9% for FY25 |
| India business volume growth | +1.1% vs IPM volume growth of 0% |
| India business IQVIA growth | 6.3% |
| PAN brand MAT growth | 12.8% vs market growth of 7.3% |
| U.S. business H1 performance | 15% degrowth, with 6% price erosion |
| U.S. business full-year outlook | Flattish to mid-single-digit erosion |
| U.S. back orders | 2%, down from 38% at start of year |
| ROW markets growth (excl. U.S. and Chile) | ~30% in Q2 |
| Chronic portfolio share of domestic business | ~20% |
| Trade generic share of domestic business | ~20% |
| Net cash | ~₹4,250 cr as of 30th September |
| Pre-operating expenses for MedTech and Enzene (full year) | ₹60–70 cr (revised from ~₹100 cr) |
| Enzene U.S. plant capex | ~₹450 cr |
| Biosimilars launched to market | 7 products |
| U.S. ANDA approvals | 145 products approved, ~100 in market |
| FY24 failure-to-supply penalties (U.S.) | ~₹140 cr |